Roughly 1 million children under age 2 are treated topically for atopic dermatitis in the United States each year, yet the approved options for that specific slice of the population remain narrow, which is precisely why the FDA’s acceptance of Arcutis’ supplemental NDA for roflumilast cream 0.05% (ZORYVE) carries real clinical weight. The agency has set a PDUFA target action date of February 23, 2027, and if the review goes cleanly, Arcutis will have extended a single molecule’s label from toddlers aged 2 to 5 all the way down to infants at 3 months, a span that covers the window when atopic dermatitis most frequently first appears.

The evidentiary package is modest by Phase 3 standards but purposeful in its design. The pivotal support comes from the open-label INTEGUMENT-INFANT study, which enrolled 101 infants and tracked safety, tolerability, and exploratory efficacy over 4 weeks, supplemented by a 19-patient Phase 1 pharmacokinetic study. Among the 96 infants who completed the full treatment period, 34.4 percent achieved vIGA-AD success (a score of clear or almost clear with at least a two-grade improvement from baseline) and 58.3 percent hit EASI-75. The itch signal was also notably rapid: 46.6 percent of caregivers reported at least a 25 percent improvement in pruritus within 10 minutes of the first application. No new safety signals emerged, and the PK and tolerability profile tracked consistently with prior data from the 2-to-5 age cohort, which is the pharmacological argument Arcutis needs the FDA to accept.

The competitive context matters here. Crisaborole ointment 2% (Eucrisa) is already approved for mild-to-moderate atopic dermatitis down to 3 months as a steroid-free topical option, so this space is not without a non-steroidal incumbent. Tacrolimus (Protopic) and pimecrolimus (Elidel) are both labeled for age 2 and older, leaving the under-2 segment with limited approved calcineurin inhibitor coverage. Roflumilast’s PDE4 mechanism, once-daily dosing, and formulation free of propylene glycol, ethanol, and fragrances give Arcutis a distinct clinical story to tell prescribers who are already wary of applying topical steroids to rapidly developing infant skin.

The single number to track between now and February 2027 is that 58.3 percent EASI-75 rate. FDA reviewers evaluating an open-label trial without a placebo arm will scrutinize whether that responder rate is clinically meaningful or inflated by the natural course of a four-week inflammatory flare. How the agency weighs that open-label design against unmet need in a vulnerable pediatric subgroup will define both this approval and the precedent it sets for future infant dermatology submissions.

Source link: https://www.globenewswire.com/news-release/2026/07/08/3324020/0/en/FDA-Accepts-Supplemental-New-Drug-Application-for-Arcutis-ZORYVE-roflumilast-Cream-0-05-for-the-Treatment-of-Mild-to-Moderate-Atopic-Dermatitis-in-Infants-Down-to-3-Months.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.